Fourth Frontier, a med-tech firm from New York and Bangalore, announced that their continuous ECG monitor, Frontier X Plus, received U.S. FDA’s 510(k) clearance. The device, worn around the chest, wirelessly relays ECG data to remote dashboards, accurately identifying cardiac rhythms such as Bradycardia, Tachycardia, Normal Sinus Rhythm, and Atrial Fibrillation. Demonstrating high signal quality during various movements, it matches the accuracy of traditional 12-lead ECGs in detecting arrhythmias through trials in India and the US.
Cardiovascular Disease (CVD), causing one death every 33 seconds, is a leading cause of death in the US, with Atrial Fibrillation cases projected to increase. Fourth Frontier’s CEO, Manav Bhushan, highlights the device’s potential in early detection of cardiovascular issues, especially in active individuals with heart health risks. The company plans to partner with diagnostic and rehab centers in the US, offering AI-driven remote monitoring services.
Read more: Revolutionizing Heart Health: Frontier X Plus Gains FDA Clearance (business-standard.com)
14-November-2024
#fda #fourthfrontier #frontierxplus #banglore #fdaclearnace #newyork